Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00098228
Other study ID # CQAB149B2205
Secondary ID
Status Completed
Phase Phase 2
First received December 3, 2004
Last updated October 24, 2011
Start date July 2004
Est. completion date December 2004

Study information

Verified date October 2011
Source Novartis
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.


Recruitment information / eligibility

Status Completed
Enrollment 686
Est. completion date December 2004
Est. primary completion date December 2004
Accepts healthy volunteers No
Gender Both
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria:

- Diagnosis of COPD

- Age 40-75 years

- Smoking history

Exclusion Criteria:

- Other serious disease

- Allergy to QAB149

- Respiratory tract infection

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • COPD
  • Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
QAB149


Locations

Country Name City State
United States ClinSite, Inc. Ann Arbor Michigan
United States University of Michigan Health System Ann Arbor Michigan
United States University Medical Associates, LLP Augusta Georgia
United States Radiant Research - Atlanta West Austell Georgia
United States Madrona Medical Group Bellingham Washington
United States UAB Pulmonary Research Birmingham Alabama
United States St. Elizabeth's Medical Center Brighton Massachusetts
United States University of Noth Carolina--Pulmonary Division Chapel Hill North Carolina
United States Low Country Lung and Critical Care Charleston South Carolina
United States Asthma & Allergy Res. Associates Dallas Texas
United States USC Rancho Amigos Medical Center Downey California
United States Radiant Research Encinitas California
United States River Road Medical Group Eugene Oregon
United States Physician's Research Center Hartford Connecticut
United States Pulmonary Respiratory Institute of Southeast Michigan Livonia Michigan
United States Allergy Research Foundation , Inc Los Angeles California
United States David Geffin UCLA School of Medicine Los Angeles California
United States University of Miami School of Medicine Miami Florida
United States Clinical Research Institute Minneapolis Minnesota
United States Minnesota Lung Center Minneapolis Minnesota
United States Southern California Research Mission Viejo California
United States Diagnostic & Medical Clinic Mobile Alabama
United States The University of South Alabama Medical Center Mobile Alabama
United States Central Texas Health Research New Baunfels Texas
United States New Orleans Center for Clinical Research New Orleans Louisiana
United States Sneeze, Wheeze & Itch Associates, LLC Normal Illinois
United States New England Clinical Research North Dartmouth New Hampshire
United States Oklahoma Allergy and Asthma Clinic Oklahoma City Oklahoma
United States VA Medical Center Oklahoma City Oklahoma
United States Creigton University Omaha Nebraska
United States Univ. of Nebraska Medical Center--Pulmonary Research Omaha Nebraska
United States California Allergy & Asthma Medical Group Palmdale California
United States Cordova Medical Center Pensacola Florida
United States Crescent Clinical Research Pensacola Florida
United States Pulmonary Associates Phoenix Arizona
United States Allergy Associates Research Center Portland Oregon
United States North Carolina Clinical Research Raleigh North Carolina
United States Asthma and Allergy Center of Chicago S.C. River Forest Illinois
United States AAIR Reseach Center Rochester New York
United States Sylvana Research San Antonio Texas
United States Allergy Associates Medical Group, Inc San Diego California
United States Allergy & Asthma Associates of Santa Clara Research Center San Jose California
United States Upstate Pharmaceutical Research Simpsonville South Carolina
United States Princeton Center for Clinical Research Skillman New Jersey
United States Pulmonary & Allergy Associates Springfield New Jersey
United States The Clinical Research Center St. Louis Missouri
United States Bensch Clinical Research Associates Stockton California
United States Pulmonary Consultants, PLLC Tacoma Washington
United States USF Asthma, Allergy & Immunology, Clinical Research Unit Tampa Florida
United States Center for Clinical Research Tauton Massachusetts
United States Healthcare Research Consultants Inc. Tulsa Oklahoma
United States Trinity Clinic Office of Research Admin. Tyler Texas
United States Rocky Mountain Center for Clinical Research Wheat Ridge Colorado
United States Cloverdale Research Facility Winston Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pulmonary function measured between 22 and 24 hours after dosing on Day 1
Secondary Pulmonary function measured on days 1 and 7 at various intervals after dosing
Secondary Safety measurements
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A